ClinicalTrials.gg
RecruitingNCT06898606COGUNILAUpdated Mar 27, 2026

Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression

A Phase 1/2 interventional study of Psilocybin and Psilocyn and Placebo in Depressive Disorder, sponsored by Federal University of Latin American Integration. Recruiting at 1 site in Brazil. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Federal University of Latin American Integration · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Depressive Disorder with a site in Brazil — 3 open to participants now, 5 under way, 2 of them phase 3. Depressive Disorder · Brazil.

Planned enrollment
16th of 17
24 · median 90
Started
2024
the only one that year
Phase 1/2
Only one
of the 18
Registered
15th of 18
by date
Lead sponsor
1 of 18
Federal University of Latin American Integration

Among the 18 studies in Depressive Disorder with a site in Brazil, this one is the 16th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2024, is the only one in phase 1/2, and was the 15th registered.

Depressive Disorder

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

3 of the 18 studies in Depressive Disorder with a site in Brazil are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Depressive Disorder with a site in Brazil, or all of them as a file.
02

Study summary

This Phase 2a pilot, exploratory, randomized, double-blind, placebo-controlled, parallel-group trial will estimate whether concurrent fluoxetine alters the antidepressant effect, acute psychedelic experience, or safety of a psychedelic-assisted psychotherapy session in adults with treatment-resistant major depressive disorder (TRD). Eligible participants (ages 25-64) have DSM-5-TR MDD, moderate-severe, MADRS ≥20, and partial response in the current episode (≥1 adequate antidepressant trial of 6-12 weeks with \<50% symptom reduction). All participants receive one dosing session with 3g of standardized Psilocybe mushrooms - with batch assay (e.g., LC-MS) to determine the amount of psilocybin and psilocin present in the sample - with manualized preparation and integration. Participants are randomized 1:1 to fluoxetine 20 mg/day or matching placebo for 4 weeks, started 2 weeks before the psychedelic session and continued 2 weeks after. Masking is quadruple (participant, care provider, investigator, outcomes assessor). The primary outcome is change in MADRS from Baseline to Week 4, assessed by a remote, blinded rater. Key secondary outcomes include response (≥50% MADRS reduction) and remission (MADRS ≤10) at Week 4, and durability at Week 6. Exploratory outcomes assess the psychedelic experience (5D-ASC, SOCQ), psychological flexibility (AAQ-10), and safety/tolerability (UKU and adverse events). Findings will be interpreted as estimates with 95% confidence intervals to inform the design of a subsequent confirmatory trial.

Read the detailed description

This is a Phase 2a pilot, exploratory, randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to estimate the effect of concurrent fluoxetine on the efficacy, acute psychedelic experience, and safety of a psychedelic-assisted psychotherapy session in adults with treatment-resistant major depressive disorder (TRD).

Rationale. Selective serotonin reuptake inhibitors (SSRIs) rapidly increase synaptic 5-HT via SERT blockade (days), whereas receptor-level adaptations (e.g., 5-HT2A down-regulation/desensitization) typically require weeks. By administering the psychedelic session after 2 weeks of fluoxetine (and continuing fluoxetine for 2 additional weeks), the study primarily probes the impact of SERT blockade per se on the psychedelic experience and antidepressant outcomes, while minimizing later, slower receptor adaptations. The design-psychedelic for both arms with blinding of fluoxetine vs matching placebo-also improves masking compared with classic "psychedelic vs placebo" trials and directly addresses the practical question of whether SSRI co-administration attenuates, has no meaningful impact, or improves tolerability.

Participants and eligibility. Adults ≥25 and \<65 years with current DSM-5-TR MDD, moderate to severe, confirmed by SCID-5, and MADRS ≥20 at baseline. TRD is defined here as Partial Response in the current episode: ≥1 adequate antidepressant trial (therapeutic dose for ≥6-12 weeks, adherence ≥80%) with \<50% symptom reduction or clinically significant residual symptoms. Key exclusions include bipolar/psychotic disorders (personal) or first-degree family history, acute suicide risk, contraindications to study medications, unstable medical illness, and current use of serotonergic agents that cannot meet protocol-defined washout. (Full Inclusion/Exclusion lists appear in the Eligibility section.)

Interventions. All participants receive a single psychedelic-assisted session with manualized preparation (2 sessions), dosing-day support, and integration (2 sessions). Administration will be carried out with 3g of standardized Psilocybe mushrooms for all participants, with batch assay (e.g., LC-MS) to determine the amount of psilocybin and psilocin present in the sample. Participants are randomized 1:1 to:

Fluoxetine 20 mg/day for 4 weeks (started 2 weeks before the psychedelic session and continued 2 weeks after), or Matching placebo for 4 weeks on the same schedule. Randomization and masking. Allocation is randomized 1:1, stratified by baseline severity (MADRS 20-29 vs ≥30) using permuted blocks of variable size. Masking is quadruple (participants, care providers, investigators, and outcome assessors). Fluoxetine and placebo are provided in identical capsules; blinding integrity is assessed post-dose and at Week 4 (guess + confidence).

Assessments and instruments. Depressive symptoms are measured primarily with MADRS (Baseline, Week 1, Pre-dose/Week 2, Week 4, Week 6). For characterization/triage, HAM-D-21 may be used at baseline. The psychedelic experience is measured with 5D-ASC (6-24 h post-dose) and SOCQ (\~24 h post-dose). Psychological flexibility is assessed with AAQ-10 (Baseline, Week 4, Week 6). Safety is captured with the UKU Side Effect Rating Scale at Baseline, Week 1, Pre-dose/Week 2, 24-48 h post-dose, Week 4, Week 5 and Week 6; adverse events and serious adverse events are recorded throughout.

Outcome measures. Primary outcome: Change in MADRS total score from Baseline to Week 4. Key secondary outcomes: Response (≥50% MADRS reduction) at Week 4; Remission (MADRS ≤10) at Week 4; durability (Baseline→Week 6 change); UKU totals/subscales and incidence of adverse events (any, moderate-severe) and serious adverse events.

Exploratory outcomes: 5D-ASC total/domains and proportion meeting "complete mystical experience"; SOCQ selected domains; AAQ-10 changes (Baseline→Week 4/6); correlations between psychedelic-experience metrics and antidepressant outcomes; comparative profiles of adverse effects between arms.

Statistical approach. The primary analysis compares arms using ANCOVA for Week-4 MADRS, adjusting for baseline MADRS (continuous). Results are presented as adjusted mean difference, 95% confidence interval, and standardized effect size (e.g., Hedges g). Given the pilot nature (N=24), inference is estimative rather than confirmatory; findings are interpreted with reference to a clinically meaningful margin for exploratory non-inferiority (e.g., -4 MADRS points). Secondary and exploratory outcomes are summarized with effect estimates and 95% CIs; p-values, if reported, are descriptive. A linear mixed model using all time points may be used as a sensitivity analysis for missing data assumed missing-at-random.

Safety and oversight. Safety monitoring includes systematic UKU assessments and continuous adverse-event surveillance from consent through Week 6, with prespecified criteria for temporary interruption or discontinuation. Concomitant medications that could compromise masking or interact serotonergically are restricted per protocol; permitted rescue options and timing windows are specified to protect outcome integrity.

This Phase 2a pilot aims to inform feasibility, mechanism, and effect size by directly testing whether concurrent fluoxetine meaningfully alters the acute psychedelic experience, antidepressant response, or tolerability/safety of psychedelic-assisted therapy in TRD.

03

Conditions studied

  • Depressive Disorder

Keywords

  • Psilocybin
  • Depression
  • Fluoxetine
  • Treatment
  • Psychedelics
04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria Age: ≥25 and \<65 years. Diagnosis: Current Major Depressive Disorder (MDD), moderate to severe, per , confirmed with SCID-5.

Baseline severity: MADRS ≥20 at baseline (reassessed at the pre-dose visit to confirm ongoing eligibility).

Partial Response in the current episode (PRD): ≥1 adequate antidepressant trial in this episode (therapeutic dose for ≥6-12 weeks, adherence ≥80%) with \<50% symptom reduction or residual symptoms.

Clinical stability and ability to provide ; willingness to comply with all study procedures (preparation, dosing session, integration, and follow-ups).

: For participants with , negative pregnancy test and agreement to use effective contraception during the study.

Exclusion Criteria Psychiatric disorders: Bipolar I/II disorder, any psychotic disorder, or current MDD with psychotic features; first-degree family history of psychotic or bipolar disorder.

Suicide risk: Acute suicidal risk, e.g., active suicidal ideation with intent or plan, recent attempt, or clinical judgment requiring urgent intervention.

Interacting medications: Current use of serotonergic antidepressants (SSRI/SNRI/MAOI, clomipramine) or other pro-serotonergic agents (e.g., triptans, linezolid, lithium, tramadol, dextromethorphan) that cannot be discontinued per protocol-defined washout.

Other psychotropics: Unstable doses of antipsychotics, mood stabilizers, or long-acting benzodiazepines within the last 2 weeks; need for medications that would compromise blinding on the dosing day.

Psychotherapy changes: Initiation or major change in psychotherapy within 2 weeks prior to baseline (to preserve clinical stability).

Medical conditions: Clinically significant or unstable medical illness (cardiovascular, neurological, hepatic, renal), prolonged , known / to fluoxetine or study materials.

Pregnancy or breastfeeding. Substance use: Current substance use disorder (excluding nicotine/caffeine) within the past 3 months; non-medical cannabis use that cannot meet the pre-dose abstinence window (e.g., ≥72 h).

Any condition that, in the investigator's opinion, would make participation unsafe or interfere with the assessments.

Washout note (to include in Procedures/Eligibility):

SSRIs/SNRIs: 7 days or ≥5 half-lives; prior fluoxetine: ≥6 weeks; MAOIs: ≥14 days before randomization/dosing. Participants must be willing and able to follow the schedule.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Psilocybin + Fluoxetine

    2 preparation sessions for the psychedelic experience 1. dosing session with 3g Psilocybe mushrooms (single oral dose), with psychotherapy assistance 2. integration sessions Fluoxetine 20 mg/day for 4 weeks (started 2 weeks before dosing and continued 2 weeks after)

    Drug: Psilocybin and Psilocyn · Behavioral: Psychotherapy-assisted session · Drug: Fluoxetine

  • Placebo comparator
    Psilocybin + Placebo

    2 preparation sessions for the psychedelic experience 1. dosing session with 3g Psilocybe mushrooms (single oral dose), with psychotherapy assistance 2. integration sessions Pharmaceutical grade talc, matching placebo (identical capsules), daily for 4 weeks (started 2 weeks before dosing and continued 2 weeks after).

    Drug: Psilocybin and Psilocyn · Drug: Placebo · Behavioral: Psychotherapy-assisted session

Interventions

  • DrugPsilocybin and Psilocyn

    Drug page: PsilocybinStudies of PsilocybinPsilocybin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral dose administered via Psilocybe mushrooms material batch-assayed by LC-MS to standardize psilocybin and psilocyn content.

  • DrugPlacebo

    Matching capsules, once daily for 4 weeks (-14 to +14 days).

  • BehavioralPsychotherapy-assisted session

    Same manualized procedures as Arm 1.

  • 20 mg/day for 4 weeks (-14 to +14 days relative to dosing day).

06

What researchers measure

Primary outcomes

  1. Montgomery-Åsberg Depression Rating Scale (MADRS)

    The primary antidepressant outcome is the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline (Day 0) to Week 4. MADRS ranges 0-60 (higher = more severe). Interviews will be conducted by a remote, blinded, independent assessor using the structured interview guide at Baseline, Week 1, Pre-dose (Week 2), Week 4 and Week 6. The primary contrast will be the adjusted difference between arms at Week 4 (ANCOVA controlling for baseline MADRS); effect size and 95% CI will be reported.

    Time frame: 4 weeks

Secondary outcomes

  1. Montgomery-Åsberg Depression Rating Scale (MADRS)

    Proportion of participants achieving ≥50% reduction in MADRS total score from baseline to Week 4.

    Time frame: 4 week

  2. MADRS Remission

    Proportion of participants with MADRS total score ≤10 at Week 4.

    Time frame: 4 week

  3. Durability of Antidepressant Effect

    Change in MADRS total score from baseline to Week 6.

    Time frame: 6 week

  4. Side Effect Rating Scale UKU

    UKU Side Effect Rating Scale total and subscales (psychic, neurologic, autonomic, sexual); incidence of adverse events (any; moderate-severe) and serious adverse events.

    Time frame: Baseline; Week 1; Pre-dose (Week 2); 24-48 h post-dose; Week 4; Week 6

Other outcomes

  1. Quality of Psychedelic Experience (SOCQ)

    States of Consciousness Questionnaire (SOCQ) selected domains (pre-specified) to characterize phenomenology beyond MEQ-30 and explore correlations with antidepressant outcomes.

    Time frame: ~24 h after the dosing session

  2. Acceptance and Action Questionnaire - AAQ-10

    Change in Acceptance and Action Questionnaire (10- item) score from baseline to Week 4 and Week 6; exploratory correlations with ΔMADRS and 5D-ASC/SOCQ.

    Time frame: Baseline to Week 4; Baseline to Week 6

  3. 5-Dimensions Altered States of Consciousness (5D-ASC)

    Change in 5-Dimensions Altered States of Consciousness (5D-ASC) total and domain scores to assess the global and detailed phenomenology of the psychedelic experience and to explore correlations with antidepressant outcomes.

    Time frame: 24 hours after the dosing session

07

Study locations

1 of 1 sites recruiting
  • Federal University of Latin American Integration
    Foz do Iguaçu, Paraná 85870-650, Brazil
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Aug 2026, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2024
First posted
Mar 27, 2025
StartActual
Sep 5, 2024
Primary completionEst.
Aug 20, 2026
CompletionEst.
Nov 20, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06898606
Lead sponsor
Federal University of Latin American Integration
Responsible party
Sponsor
First posted
Mar 27, 2025
Start date
Sep 5, 2024
Primary completion
Aug 20, 2026 (estimated)
Completion
Nov 20, 2026 (estimated)
Last update
Mar 27, 2026

Study contacts

Francisney P Nascimento, 1
Contact
ensaios.clinicos.lcp@unila.edu.br
+55 45 99933-3479
Francisney P Nascimento, 1
study director · Federal University of Latin American Integration

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluoxetine

Start the discussion